凡德他尼是抑制血管内皮生长因子受体(vascular endothelial growth factor receptor, VEGFR)和内皮生长因子受体(endothelial growth factor receptor, EGFR)的小分子药物,本研究旨在系统评价凡德他尼作为二线方案治疗非小细胞肺癌(non-small cell lung cancer, NSCLC)的有效性和安全性。. Here, EGFR is linked to non-small cell lung carcinoma.